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Introduction
More than 65,000 people will be diagnosed with colorectal can-
cer (CRC) in Germany in 2016, and more than one-third of them 
will not survive. However, data of the German Federal Statistics 
Office (Destatis) show a clear trend towards lowered mortality 
from CRC (fig. 1). Furthermore, the cumulative number of patients 
hospitalized for CRC exceeds 80,000 per year. Given the fact that 
surgical removal of colon cancer represents the only curative op-
tion, and R0 resections, particularly in metastatic situations, dra-
matically impacts long-term survival [1], these data illustrate the 
importance of surgical therapy in most treatment concepts for 
CRC [2].
Interestingly, the general principles of colorectal surgery have 
remained unchanged over many years [1, 3–6]. Thus, colorectal 
surgery and especially its technical aspects can seem like an every-
day routine set of procedures. The main goals of surgical treatment 
for CRC are avoidance of recurrence and metastatic spread, treat-
ment of complications, and maintenance of quality of life. 
However, certain subtle differences in surgical treatment prac-
tices exist, which have become the subject of debate in recent years. 
The most relevant differences in our view include:
i) Optimal lymph node yield and related to it complete mesocolic 
excision (CME) for colon cancer (this question has been an-
swered for stage II and III rectal carcinoma since total meso-
rectal excision (TME) has become standard);
ii) Applicability of laparoscopic surgical strategies, including sin-
gle incision laparoscopic surgery (SILS), natural orifice trans-
luminal endoscopic surgery (NOTES), and robotic laparo-
scopic surgery;
iii) Strategies to surgically treat colorectal metastatic disease as 
well as peritoneal spread; and
iv) Strategies for the surgical removal of extensive recurrent 
colorectal disease.
This article provides insights into the current level of knowledge 
addressing these issues. For this purpose, PubMed, EMBASE, and 
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Summary
Background: Although colorectal surgery is long estab-
lished as the mainstay treatment for colon cancer, cer-
tain topics regarding technical fine-tuning to increase 
postsurgical recurrence-free survival have remained a 
matter of debate throughout the past years. These in-
clude complete mesocolic excision (CME), treatment 
strategies for metastatic disease, significance of hyper-
thermic intraperitoneal chemotherapy (HIPEC), and sur-
gical techniques for the treatment of colorectal cancer 
recurrence. In addition, new surgical techniques have 
been introduced in oncologic colorectal surgery, and 
their potential to provide sufficiently radical resection 
has yet to be proven. Methods: A structured review of 
the literature was performed to identify the current state 
of the art with regard to the mentioned key issues in 
colorectal surgery. Results: This article provides a com-
prehensive review of the current literature addressing 
the above-mentioned current challenges in colorectal 
surgery. The focus lies on the impact of CME and, in re-
lation to this, on lymph node dissection, as well as on 
treatment of metastatic disease including peritoneal 
spread, and finally on the treatment of recurrent disease. 
Conclusion: Uniformly, the current literature reveals that 
surgery aiming at complete malignancy elimination 
within multimodal treatment approaches represents the 
fundamental quantum leap for the achievement of long-
term tumor-free survival.
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public search engines were searched for relevant literature on the 
current state of the art regarding the management of CRC. Search 
terms were ‘colorectal cancer’ and ‘surgery’ combined with the 
terms of the subheadings of this manuscript, namely ‘resection’, 
‘CME’ and ‘TME’, ‘lymph node dissection’, ‘hepatic metastases’, 
pulmonary metastases’, ‘peritoneal metastases’, ‘HIPEC’, and ‘re-
current disease’ or ‘relapse’. The time period covered was 2000–
2016. A total of 99 articles were identified pertaining to current 
surgical strategies. Search results relevant to the above topics have 
been amended with personal clinical experience in ord†er to give a 
comprehensive overview of up-to-date treatment options and fu-
ture perspectives.
Current Surgical Treatment Strategies for  
Colorectal Cancer
Lymph Node Dissection
Without doubt, en bloc excision of the lymphatic drainage of the 
tumor, including the lymph nodes located therein, has been shown 
to fundamentally influence the long-term prognosis after surgery 
for CRC. In this regard, it has been clearly shown by several groups 
that an increasing number of lymph nodes examined by patholo-
gists correlates with better survival [6–8]. This has even been shown 
in patients without lymph node involvement. Apart from these ob-
servations, the total number of removed lymph nodes appears to 
reflect only half the truth about the correlation between lymph node 
involvement and survival. Rather, the number of examined lymph 
nodes mirrors an appropriate processing of the specimen by the pa-
thologist allowing stratification in terms of future risk of metastatic 
disease. In addition, increased colon cancer survival has been 
shown to be associated with a decreasing ratio of metastatic to ex-
amined lymph nodes [9, 10]. In these studies, the number of exam-
ined lymph nodes ranged between 11 and 25, which appears rather 
low and may be easily achieved with a standardized excision tech-
nique combined with CME (and TME in rectal cancer) in the meso-
colic plane with central vascular ligation [11]. 
Indeed, several studies have suggested improved quality of sur-
gical specimens and oncologic outcome following CME for colon 
cancer [12]. As with TME, the CME concept involves the complete 
removal of the intact mesentery and high ligation of the vascular 
supply at its point of origin (fig. 2a–c) [13]. Thereby, the embryo-
logical planes are respected during surgery. However, in contrast to 
TME, routine implementation of CME has not yet been achieved. 
Many studies have reported increased lymph node harvest, less 
morbidity, reduced locoregional recurrence, and extended cancer-
specific survival with CME [12]. This might result in an upstaging 
of patients and in a higher number of patients for whom chemo-
therapy is indicated. However, some authors suggest that routine 
implementation may cause longer operation times [13], which can-
not be supported based on our center’s experience. The majority of 
available evidence was generated by retrospective series. West et al. 
[11] evaluated resection specimens from a center where CME is 
routinely performed and compared them to standard specimens 
from another center. The CME specimens were shown to be more 
frequently resected in the correct anatomic plane and to have a 
higher lymph node count. Storli et al. [14] reported improved 
3-year overall (88 vs. 79%; p = 0.003) and disease-free survival (82 
vs. 74%; p = 0.026) when CME was applied. Cancer-specific sur-
vival tended to be better (95 vs. 90%; p = 0.067). In another study, 
Galizia et al. [15] observed that locoregional recurrence was not 
experienced in CME patients compared to non-CME patients 
(21%). The risk of cancer-related death was decreased by over one 
half in CME patients. However, the CME group was also character-
ized by significantly higher operation time and blood loss. Further-
more, there were significantly more early cancer stages in the CME 
group. In a retrospective population-based study by Bertelsen et al. 
[16] (Danish Colorectal Cancer Group), the CME group showed 
better 4-year disease-free survival (86%) than the conventional re-
section group (76%, p = 0.001). Especially patients with stage I and 
II disease seemed to benefit from CME. As there are multiple 
causes of potential bias regarding the survival benefit from CME in 
these retrospective studies, these comparisons should be inter-
preted with caution [13]. Thus, as data from large multicenter ran-
domized trials are missing, CME has not yet been introduced as a 
Fig. 1. Current data 
regarding develop-
ments in CRC-related 
hospital cases and mor-
tality.
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standard approach. However, increasing evidence indicates that 
implementation of CME surgery would improve outcomes for 
colon cancer patients.
TME, however, was proposed many years earlier by Heald [3], 
and represents a fundamental improvement in the resection of rec-
tal tumors. Nowadays, the completeness of the TME, and with that 
the quality of surgical tumor removal, may be expressed as the 
pathologic circumferential resection margin (pCRM). An intact 
and complete pCRM has been identified to lower local recurrence 
rates, whereas it may not impact on the development of distant 
metastases [17, 18].
Can an Appropriate Lymph Node Number and Ratio Be Gained 
with Laparoscopic Techniques?
In numerous studies, concerns that a minimally invasive ap-
proach may compromise survival by failing to achieve proper on-
cologic clearance and adequate staging or by altering the pattern of 
recurrence could be alleviated. Besides cosmetic aspects, similarity 
in short-term patient-related benefits such as reduction in narcot-
ics and oral analgesics as well as earlier resumption of bowel activ-
ity and hospital discharge has been demonstrated in multiple trials 
[19–23]. More importantly, there were no significant differences in 
overall disease-free survival and time to recurrence, as well as port 
or wound site metastases for laparoscopic-assisted techniques [24–
28]. To date, laparoscopic surgical techniques for cancer of the sig-
moid and rectum represent an established component of the work 
of every colorectal surgery department. Although technically feasi-
ble with the same quality and reproducibility, minimally invasive 
surgery for upper colon sections, such as the right-, transverse-, 
and left-sided colon, never became accepted as clinical standard in 
the same way as resections of the rectosigmoid. To date, in Ger-
many only 10% of colon resections are performed as minimally in-
vasive surgery, whereas approximately 30% of sigmoid resections 
are performed laparoscopically. A Cochrane systematic review was 
performed including 12 randomized clinical trials involving 3,346 
patients for the analysis of long-term outcome of open versus lapa-
roscopic CRC resection. Analyzing only colon cancer cases, no sig-
nificant difference for recurrence at the primary tumor site, general 
tumor recurrence, or tumor-related mortality was detected [29]. 
Furthermore, it has to be pointed out that the most important 
aspect for the postsurgical oncologic prognosis – an appropriate 
lymph node yield within en bloc resection with CME – may also be 
achieved with laparoscopic surgery [19, 24, 30]. 
Further laparoscopic techniques such as SILS or NOTES have 
been proven to be efficient techniques and are discussed in detail in 
a separate article of this issue. 
Treatment Strategies in Advanced Stages of  
Colorectal Cancer
Treatment regimens for advanced stages of CRC are markedly 
more complex and require a differentiated strategy compared to 
the treatment of a primary CRC without local complications. 
The metastatic spread arising from CRC may be categorized 
into three main forms: i) hepatic metastasis; ii) pulmonary metas-
tasis; and iii) peritoneal carcinosis.
Hepatic Metastasis
Characteristic forms of occurrence must be distinguished. First 
of all, metastases may occur metachronously or synchronously ac-
cording to the primary diagnosis; second, the disease may occur in 
an oligometastatic as well as diffuse pattern, and those may be re-
sectable, resectable after pretreatment, or non-resectable. Surgical 
resection of hepatic metastatic CRC became one of the crucial an-
chors of treatment impacting patient prognosis. Recently, it was im-
pressively shown that the advances in interdisciplinary treatment 
concepts have led to a marked improvement in long-term survival 
Fig. 2. a Schematic illustration of the anatomic plane for complete mesocolic excision (CME) in right-sided hemicolectomy. b Crucial intraoperative step for 
CME in right-sided hemicolectomy. Mesocolon and mesoileum have to be mobilized along Toldt’s fascia to the duodenum and lower edge of the pancreas. The 
vascular trunks of the middle (transverse) colon and ileal artery/vein are the dissection margins to the left. c Crucial intraoperative step for CME in sigmoid resec-
tion hemicolectomy. The inferior mesenteric vein should be divided at the lower edge of the pancreas (triangles); the left superior marginal vein may be preserved 
for improved venous drainage of the relocated descending colon and left colic flexure. Note that the pancreas is still covered by the mesenteric section of the trans-
verse colon.
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[31]. However, with these multimodal concepts, some recent find-
ings have to be taken into account. First of all, in the surgical treat-
ment of colorectal hepatic metastases, achievement of an R0 situa-
tion appears to be mandatory for a positive long-term prognosis 
even in the era of perioperative chemotherapy [32–36]. However, in 
some patients, resectability criteria may not be fulfilled at the time 
of diagnosis, but may be achieved by reducing the size and/or num-
ber of the metastases preoperatively. This requires chemotherapy 
and/or additional local ablative therapy as pretreatment [37–41]. 
However, if bowel obstruction by the primary cancer complicates or 
inhibits effective further treatment, its prompt resection or a de-
compressing stoma to prevent an ileus are indicated. 
Depending on the local stage and the intrahepatic tumor burden, 
sequential or synchronous resection of malignant lesions may be 
considered. The question of whether the primary colon cancer or the 
metastasis should be resected first still remains a matter of debate. In 
clinical situations with dominant hepatic tumor burden compared 
to the primary cancer, a liver-first approach is recommended. This 
approach should especially be considered when neoadjuvant or ad-
juvant chemotherapy regimens with the aim of hepatic tumor con-
trol are likely to fail. This strategy was invented in the face of the 
facts that surgical treatment of the primary would delay liver resec-
tion, radiochemotherapy for the primary tumor in rectal cancer is 
ineffective to control large hepatic metastases, and resection of the 
primary stimulates growth of the hepatic metastases [42]. 
However, it was shown that concomitant hepatic and colon re-
sections may slightly decrease perioperative morbidity, with simi-
lar overall survival and quality of life [39, 43, 44]. In these studies, 
no sufficient data was made available on progression-free survival. 
Other studies revealed no difference with regard to hospital stay 
and perioperative morbidity [45, 46]. In summary, simultaneous 
resections appear to be recommendable for patients with limited 
hepatic disease. In this context, the 2-stage liver resection may be 
combined with a simultaneous approach for the colon and liver. 
For example, if the liver displays bilobar metastatic disease with a 
high malignant burden on one side (supposedly with decreased 
metabolic function of this hepatic lobe), resection of the affected 
segment(s) may be performed simultaneously to the resection of 
the primary tumor, with subsequent chemotherapy (to counteract 
the hypertrophy stimulus on liver metastases on the contralateral 
side), followed by a definitive tumor clearance resection in the 
remnant liver. To achieve total tumor clearance in metastatic CRC, 
all strategies to improve resectability, i.e. portal vein embolization 
with hepatic hypertrophy on the contralateral side or the ‘associat-
ing liver partition and portal vein ligation’ technique, may be uti-
lized as individually adjusted treatment concepts [47–54].
Pulmonary Metastatic Disease
Equally, patients with pulmonary metastasis may benefit from 
surgical resection [55–57]. However, patient selection plays a cru-
cial role with regard to prognosis. It has been shown that the num-
ber of nodules resected is associated with long-term survival. Other 
authors have shown that bilobar dissemination, requiring surgery 
for complete removal, was not associated with any survival benefit 
[57]. In small series, a benefit following pulmonary resection was 
also shown in disease stages with combined metastatic spread [58, 
59] as well as in patients with recurrent pulmonary metastases.
Recurrent Disease
Compared to situations requiring surgery for primary tumors, 
treatment of recurrent CRC frequently requires multimodal strate-
gies (fig. 3). Several studies revealed a clear survival advantage for 
patients who were eligible for surgery in the case of recurrent rectal 
carcinoma [60–64] as well as for colon carcinoma [65, 66]. Al-
though recurrence apart from N2 situations or adjacent organ in-
vasion may be rarely expected in intraperitoneal colon carcinoma, 
a considerable number of cases may present in large-volume cen-
ters. A cohort study from Bologna compared 31 vs. 29 patients with 
predominantly intraperitoneal colon carcinoma receiving chemo-
therapy or second surgery (mixed indication), respectively [67]. 
This study revealed a prolongation of disease-free survival by 4 
months (not significant) and a markedly longer median overall 
survival (58.7 vs. 24.0 months; p < 0.001). However, when no peri-
surgical chemotherapy was applied, the median overall survival de-
creased to 30.3 months in the second-surgery group, indicating the 
importance of multimodal concepts in the treatment of colon car-
cinoma recurrence. Read et al. [66] observed local recurrence in 4% 
of patients over 5 years, and this was associated with the above-
Fig. 3. Images of a 
77-year-old man pre-
senting with a second 
local recurrence of a 
rectal carcinoma. He 
was treated with sacro-
pelvic excision and for-
mation of a descendos-
toma plus ileum con-
duit with urostoma fol-
lowing repeated 
radiation therapy and 
chemotherapy.
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mentioned lymph node status or tumor extent in 75% of the pa-
tients. In this study, an overall complication rate of 29% was noted, 
with 2.1% grade 5 complications according to the Clavien-Dindo 
classification. The Sloan Memorial Kettering Cancer Center [66] 
demonstrated a 40% recurrence rate at any location after curative 
surgery for CRC; 75% of these patients presented with locoregional 
relapse. In principal, four subgroups of local recurrence should be 
distinguished: i) anastomotic; ii) mesenteric/lymph node; iii) retro-
peritoneal; and iv) disseminated peritoneal. Besides age (>60 years) 
and the primary tumor stage (I and II vs. III and IV), this study of 
100 consecutive cases with relapse after primary curative resection 
of intraperitoneal colon carcinoma revealed a clear benefit for tu-
mor-specific survival when an R0 resection was achieved. Inde-
pendent factors associated with the possibility of an R0 resection 
included a low carcinoembryonic antigen level (<5 ng/ml), peria-
nastomotic disease, and absence of distant disease.
Another study showed that both the total number of metastases 
and the location of the metastatic disease were associated with 
prognosis [68]. Survival was strongly associated with overall tumor 
burden. Interestingly, among patients with a large tumor burden 
(>6 metastatic lesions), the relative prognostic impact of the ana-
tomic location was lower.
Nevertheless, complete resection remains the most important 
prognostic factor and should be the goal of treatment for locally 
recurrent CRC [63, 65, 66]. Multimodal and interdisciplinary treat-
ment including neoadjuvant and adjuvant therapies should be dis-
cussed for all patients. Considering the available evidence, even re-
irradiation should be considered in specific cases [64]. In the case 
of disseminated disease (type IV recurrence, see above), applica-
tion of hyperthermic intraperitoneal chemotherapy (HIPEC) 
should be discussed (see following section). The goal of complete 
tumor tissue removal is a proven concept that improves survival as 
compared to alternative methods for the control of local tumor 
growth [69]. 
Furthermore, local complications with a risk of pelvic sepsis as a 
consequence of uncontrolled destruction of adjacent structures 
may be avoided. Development of rectal carcinoma recurrence 
might require pretreatment with chemoradiation in order to limit 
the extent of resection. Recurrent disease has to be expected in 
4–11% of patients at 5 years post-surgery under optimal multi-
modal treatment conditions, despite primary R0 resection with in-
tact mesorectal fascia [64]. Interestingly, the Stockholm Colorectal 
Cancer Study Group and the Basingstoke Bowel Cancer Research 
Project were able to show that individual training of surgeons in 
the TME technique resulted in a reduction in local recurrence rates 
from 14 to 6% [70]. Without such measures, rates of 5–35% have 
been reported [69].
As standard surgical procedure with extended intrapelvic tumor 
recurrence, abdominoperineal rectal excision represents the main-
stay of therapy beyond sphincter-sparing procedures. However, 
large controlled trials repeatedly showed that total abdominoper-
ineal excision, irrespective of the tumor distance from the anorec-
tal verge, was associated with higher rates of positive CRMs and 
perforation of the mesorectal plane, which might be attributed, at 
least in part, to the surgical technique, leaving a waist on the speci-
men in the area of the pelvic levator muscle by anatomic prepara-
tion along the mesorectal fascia. Thus, in recent publications, the 
so-called extralevator abdominoperineal excision (ELAPE) has 
been propagated [71], involving a cylindrical excision including the 
narrowing part of the levator muscle. This preparation technique 
was introduced for extended and low-seated primary tumors; how-
ever, it is of particular value in recurrent rectal carcinoma, which, 
by nature, exceeds the level of the mesorectal fascia in most cases. 
For recurrent tumors infiltrating adjacent pelvic structures such 
as prostate, bladder, vagina, and uterus, complete pelvic exentera-
tion represents the optimal surgical strategy [72–74] (fig. 3). First 
described by Brunschwig in the 1960s for gynecologic tumors, this 
technique was adopted to treat extended rectal tumors. It includes 
the resection of all potentially infiltrated structures, such as bony 
pelvis, and also, where appropriate, the resection of pelvic vessels 
with vascular replacement. In keeping with established principles 
of cancer surgery, the recurrent tumor must be excised en bloc, in 
continuity with all involved structures, if local control or cure is to 
be achieved. Absence of tumor infiltration is determined intraop-
eratively by the pathologist. However, the presence of unresectable 
extrapelvic generalized disease is generally accepted as a contrain-
dication for curative resection. Clinical symptoms, such as sciatic 
nerve pain, a frozen pelvis [75], and unilateral leg edema [76], re-
quire special attention during preoperative staging with magnetic 
resonance imaging or high-resolution computed tomography, and 
are relative contraindications for resection. Ascertained infiltration 
of the proximal (S1 or higher) lumbosacral spine or lumbosacral 
plexus/sciatic nerves is considered as the limit of surgical feasibility 
[77]. 
In conclusion, optimal tuning of multimodal treatment options 
including aggressive surgical regimens may result in maximized 
disease-free survival of approximately 30% [78–80] and an overall 
survival of roughly 50% at 5 years when an R0 resection for locally 
recurrent CRC is achieved [78–81].
Peritoneal Carcinomatosis
More than 10% of patients present with peritoneal carcinoma-
tosis as a consequence of continuous regional tumor dissemination 
at the time of initial diagnosis [82, 83]. About 40% of patients with 
CRC develop peritoneal dissemination at some point in the natural 
history of this disease [84]. Moreover, peritoneal carcinomatosis is 
a common sign of tumor progression or recurrence. Patients with 
peritoneal metastases have historically been considered as having 
incurable disease with merely palliative treatment options includ-
ing supportive care, palliative surgery, and the best systemic chem-
otherapy [85]. Survival rates do not exceed 7 months according to 
the multicenter study EVOCAPE [85] with 5-fluorouracil (5-FU) 
and leucovorin, reaching up to 23.4 months with modern chemo-
therapy regimens including oxaliplatin and irinotecan [86]. How-
ever, in about 25% of the cases, there is no evidence of further dis-
tant metastasis, and the peritoneal cavity is the only site of meta-
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static disease. This suggests that in those cases, peritoneal carcino-
matosis may represent a first site of dissemination.
Therefore, it is not necessarily indicative of generalized disease, 
and Elias et al. [87] described and popularized several procedures, 
such as cytoreductive surgery (including peritonectomy) together 
with HIPEC and early postoperative intraperitoneal chemotherapy 
(EPIC), to treat peritoneal carcinomatosis [88]. Although prelimi-
nary data were viewed with great skepticism, this strategy is the 
only one that has shown curative benefits in colorectal peritoneal 
carcinomatosis. In a randomized controlled trial, Verwaal et al. 
[89] analyzed 105 patients with established peritoneal carcinoma-
tosis of colorectal or appendiceal origin, which were randomly as-
signed to cytoreductive surgery and HIPEC with mitomycin C fol-
lowed by systemic chemotherapy (5-FU and leucovorin), or to sys-
temic chemotherapy alone (5-FU and leucovorin) with palliative 
surgery as needed. Despite the high postoperative mortality rate 
(8%), the median disease-specific survival in the HIPEC-treated 
group was significantly longer (22 vs. 13 months). At a median 
follow-up of 8 years, 45% of patients of the HIPEC arm who under-
went complete cytoreduction (no residual tumor nodules) were 
still alive [89]. In another randomized controlled trial, patients fol-
lowing aggressive surgical cytoreduction and systemic therapy 
(5-FU-based) with or without HIPEC [87] were investigated. Al-
though the 2-year survival rate of patients undergoing HIPEC was 
about 60%, the difference in survival between the experimental and 
control groups was not statistically significant. Thus, the effect of 
HIPEC is not clearly defined, while cytoreduction is most likely to 
have beneficial effects. A controlled randomized clinical trial to 
prove this concept is ongoing. Together, these trials as well as sev-
eral systematic reviews of the literature indicate that i) cytoreduc-
tion in combination with HIPEC prolongs median survival of pa-
tients with CRC and peritoneal carcinomatosis up to 29 months 
and the 5-year survival rates up to 19%; ii) survival rates are even 
higher if the patients undergo complete surgical cytoreduction 
(median survival 28–60 months, and 5-year survival 22–49%); and 
iii) the overall treatment-associated morbidity and mortality rates 
are relatively high (23–44% and 0–12%, respectively) [90–92]. The 
success of this treatment strategy substantially depends on a careful 
patient selection [85, 93]. Candidates should be younger than 70 
years with a physiological age of less than 65 years. Severe cardi-
orespiratory disease, renal failure, untreated malignant neoplasm 
or a World Health Organization Index >  2 are considered con-
traindications for cytoreduction + HIPEC [93]. Furthermore, all 
patients selected for cytoreduction with curative intent should not 
present with progressive disease while on chemotherapy. As men-
tioned above, the key to successful outcome is an appropriate selec-
tion of patients in order to achieve complete cytoreduction, since 
this is an essential prognostic factor [94]. To this effect, it has been 
demonstrated that patients with incomplete cytoreduction and re-
sidual tumor   2.5 mm (completeness of cytoreduction (CC-1) 
score) do not achieve more than 6 months survival [95, 96]. Other 
major prognostic factors associated with worse outcomes are: his-
topathologic grades 2 and 3 vs. grade 1, Peritoneal Cancer Index 
> 20, lymph node-positive primary tumors, and volume of preop-
erative peritoneal metastases [88, 97, 98].
Based upon these issues, the current German guidelines for 
CRC [99] recommend surgical cytoreduction followed by HIPEC 
in patients with isolated and localized peritoneal carcinomatosis if: 
i) Peritoneal Cancer Index < 20; ii) no extra-abdominal metastases 
are present; iii) macroscopically complete cytoreduction of the 
tumor is possible; and iv) therapy is provided in specialized cent-
ers, preferably in the context of a clinical trial.
Conclusion
Aggressive surgical strategies with the aim of complete malig-
nancy elimination are associated with improved disease-free as 
well as overall survival in most cases of primary and secondary 
CRC. Surgical radicalness must be balanced with the impact on 
quality of life. Multimodal therapeutic approaches are frequently 
recommended to achieve a curative situation in combination with 
high quality of life. New technical developments, including mini-
mally invasive surgery, aiming to increase patient comfort and 
quality of life have proven their worth in oncologic surgery.
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